SAN DIEGO — Until instruments used for proteomics research become cheaper and more user-friendly, proteomics may always play second fiddle to genomic technologies in the clinical setting, according to participants in a panel discussion at the annual meeting of the US Human Proteome Organization, held here this week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.